Boston – July 7, 2016 – Cooley advised Minerva Neurosciences on its follow-on offering of 6,052,631 shares of common stock for gross proceeds of $57.5 million.
Minerva, which trades on The NASDAQ Global Stock Market, is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases.
Cooley advised the underwriters on Minerva's IPO in July 2014.
The Cooley corporate and securities team advising Minerva included Marc Recht, Miguel Vega, Rich Segal, Matt Ruderman and Maggie Siegel.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.